<DOC>
	<DOC>NCT01046864</DOC>
	<brief_summary>The purpose of this study is to determine a safe and maximum tolerable dose of Brivanib when combined with standard dose 5FU/LV and FOLFIRI.</brief_summary>
	<brief_title>Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Histological/cytological confirmed diagnosis of Gastrointestinal malignancy, except pancreatic cancer Eligible for 5FU/LV or FOLFIRI chemotherapy ECOG 01 Able to swallow and tolerate tablets Life expectancy of 3 months Unwilling to use acceptable method to avoid pregnancy of partner/self for the entire study period and up to 4 weeks after last dose Women who are pregnant or breastfeeding Pancreatic cancer Known brain metastasis, evidence of leptomeningeal disease History of thromboembolic disease Hemorrhage/bleeding events Uncontrolled or significant cardiovascular disease Any 3 or more of the following risk factors: arterial thrombosis , smoking, hypercholesterolemia, hypertension, obesity (BMS&gt;30) and diabetes Preexisting thyroid abnormality, not maintained with medication QTC (Fridericia) &gt;450 msec on two consecutive ECG's Subjects with concomitant second malignancies ( except adequately treated nonmelanoma skin, in situ carcinoma of bladder, cervix or breast, early prostate cancer) Any major surgery within 4 weeks of study drug administration Increased levels of both DDimer and Prothrombin fragment 1 +2 Arm B and C onlypositive UGT1A1 genotype of TA7/TA7 History of allergy of brivanib or drug class History of severe reactions to fluoropyrimidine therapy or irinotecan Prior therapy with brivanib</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Gastro-Intestinal Cancer, NOS</keyword>
</DOC>